Latest News Archive

Please select Category, Year, and then Month to display items
Previous Archive
23 September 2022 | Story Rulanzen Martin | Photo Rulanzen Martin
Donovan Wright
Donovan Wright is currently pursuing his PhD in South African Sign Language linguistics at the UFS.

Donovan Wright recently joined the University of the Free State (UFS) as a lecturer in the Department of South African Sign Language (SASL) and Deaf Studies. As a passionate young academic, Wright ‘found his love’ for SASL during his undergraduate years at the University of the Witwatersrand (Wits). 

In 2016, for the fulfilment of his master’s degree at Wits, Wright completed a thesis titled ‘A preliminary description of South African Sign Language syntax’. He is currently pursuing his PhD at Wits, and his research interests lie in the linguistics of SASL, which became his focus during his postgraduate studies. In his PhD research he focuses on (particular) constructions within SASL and how to best describe and analyse them. “I chose to use an approach to language and grammar not tied to how we perceive and understand spoken languages,” he says. 

‘Teaching SASL is my great passion’

His appointment as a SASL lecturer at the UFS is a fulfilment of his passion for teaching. “Sign languages are commonly misunderstood and thought to be pantomime or gesture,” he says.  “These common misconceptions are the first topic we tackle – whether by linguistic or social argument.” As a SASL linguistics lecturer he says it’s this aspect of the modules that is so rewarding, especially “seeing students realise something new about a sign they already know and have been using. Learning about language while learning a language has its benefits.” 

Empowering students is about access

Wright says access to education is a fundamental right for every student, and that empowering Deaf scholars will ultimately improve how Deaf students access information at universities and elsewhere. “While many students attend university and access their education in a language that is not their mother tongue, Deaf students using SASL are additionally learning across modalities.” 

September is designated as Deaf Awareness Month, with one important aim being to highlight and improve sign language education. The Department of South African Sign Language and Deaf Studies has planned numerous events and initiatives during this month, which will raise awareness and provide community education by visiting schools.  

“The next step is ensuring an environment in which Deaf students who choose to pursue a career in academia are not hindered. Our Deaf students are our future Deaf academics,” Wright says. 

• Members of the Department of South African Sign Language and Deaf Studies will, among other planned events, provide community interpreting services and visit schools in surrounding areas. This year the department is launching a university ‘Deaf Space’ where students, staff, or anyone wishing to engage in SASL can interact, provided you ‘leave your voice at the door’. 


News Archive

Nuclear Medicine on the forefront of cancer research
2017-07-10

Description: Nuclear Medicine on the forefront of cancer research Tags: Nuclear Medicine, cancer research, Dr Je’nine Horn-Lodewyk’s, tumour detection method, cancer, Department of Nuclear Medicine 

Dr Je’nine Horn-Lodewyk’s tumour detection method
could be the cost-effective breakthrough needed to decrease
the mortality rate in breast cancer patients.
Photo: Anja Aucamp

The field of Nuclear Medicine in South Africa and the rest of the world are expanding rapidly due to the development of hybrid cameras and new radiopharmaceuticals. These developments have a huge impact on the diagnosis and therapy of cancer.

The most advanced of these cameras, Positron emission tomography combined with normal CTs (PETCT), are not yet widely available in South Africa due to the cost of the cameras and the radiopharmaceuticals. A more cost-effective alternative can be of great benefit. To achieve this, the focus should be on developing new radiopharmaceuticals that can be used with the current cost-effective gamma cameras, according to University of the Free State researcher, Dr Je’nine Horn-Lodewyk from the Department of Nuclear Medicine.

Fluorodeoxyglucose (18F-FDG), a radiolabelled glucose analogue, is currently the radiopharmaceutical most commonly used in PET/CT imaging for mainly oncology indications. Although it is considered the gold standard for imaging in several malignancies, it does have certain disadvantages. An 18F-FDG PET/CT diagnostic imaging study can cost between R25 000 and R35 000 for a single patient in the private sector. The 18F-FDG is also more radioactive, which requires much stricter handling and shielding to avoid high radiation dosages to staff and patients.

Successful research potential innovative solution
In the search for the ideal radiopharmaceutical for tumour detection, the South African National Nuclear Energy Corporation (Necsa) developed a local synthesis process for ethylenedicysteine-deoxyglucose (EC-DG). EC-DG is also a glucose analogue similar to FDG. They succeeded in labelling the compound with Technetium-99-metastable-pertechnetate (99mTcO4-), the most common nuclear medicine isotope used for approximately 95% of nuclear medicine procedures, creating 99mTc-EC-DG.

In partnership with Dr Horn-Lodewyk, this compound was successfully used in various animal models and clinical scenarios, resulting in approval by the Medicine Control Council to use it in a human study. Research is also planned in order to investigate diagnostic accuracy in other cancers like lymphoma.  The end result of this research can produce a radiopharmaceutical that is cost effective, does not require the use of costly specialised equipment, has no significant side-effects, no special patient preparation, renders late imaging possible, and has decreased radiation risks.

Dr Horn-Lodewyk is grateful for the support of her mentor, Prof Anton Otto, as well as Dr Gert Engelbrecht, Head of the Department of Nuclear Medicine, Prof Jan Rijn Zeevaart from North-West University’s Preclinical Drug Development Platform and Necsa, and Judith Wagener from Necsa. This innovative research would also not have been possible without the financial assistance of Dr Glen Taylor and Eleanor van der Westhuizen in the Directorate of Research Development.

We use cookies to make interactions with our websites and services easy and meaningful. To better understand how they are used, read more about the UFS cookie policy. By continuing to use this site you are giving us your consent to do this.

Accept